Cargando…

Insulin resistance in COVID-19 and diabetes

BACKGROUND: The epidemiology of COVID-19 and its association with cardiometabolic disorders is poorly understood. This is a narrative review that investigates the effects of COVID-19 infection on insulin resistance in patients with diabetes. METHODS: An online search of all published literature was...

Descripción completa

Detalles Bibliográficos
Autores principales: Govender, Nalini, Khaliq, Olive P., Moodley, Jagidesa, Naicker, Thajasvarie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Primary Care Diabetes Europe. Published by Elsevier Ltd. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8031259/
https://www.ncbi.nlm.nih.gov/pubmed/33849817
http://dx.doi.org/10.1016/j.pcd.2021.04.004
_version_ 1783676143172321280
author Govender, Nalini
Khaliq, Olive P.
Moodley, Jagidesa
Naicker, Thajasvarie
author_facet Govender, Nalini
Khaliq, Olive P.
Moodley, Jagidesa
Naicker, Thajasvarie
author_sort Govender, Nalini
collection PubMed
description BACKGROUND: The epidemiology of COVID-19 and its association with cardiometabolic disorders is poorly understood. This is a narrative review that investigates the effects of COVID-19 infection on insulin resistance in patients with diabetes. METHODS: An online search of all published literature was done via PubMed and Google Scholar using the MeSH terms “COVID-19,” “SARS-CoV-2,” “coronavirus,” “insulin resistance,” and “diabetes.” Only articles that were directly applicable to insulin resistance in COVID-19 and diabetes was reviewed. RESULTS: Current data shows an increased risk of mortality in patients with diabetes and COVID-19 compared to those without diabetes. COVID-19 triggers insulin resistance in patients, causing chronic metabolic disorders that were non-existent prior to infection. CONCLUSION: Patients with diabetes are more susceptible to COVID-19 infection than those without diabetes. ACE2 expression decreases with infection, exaggerating Ang II activity with subsequent insulin resistance development, an exaggerated immune response and severe SARS-COV-2 infection.
format Online
Article
Text
id pubmed-8031259
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Primary Care Diabetes Europe. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-80312592021-04-09 Insulin resistance in COVID-19 and diabetes Govender, Nalini Khaliq, Olive P. Moodley, Jagidesa Naicker, Thajasvarie Prim Care Diabetes Review BACKGROUND: The epidemiology of COVID-19 and its association with cardiometabolic disorders is poorly understood. This is a narrative review that investigates the effects of COVID-19 infection on insulin resistance in patients with diabetes. METHODS: An online search of all published literature was done via PubMed and Google Scholar using the MeSH terms “COVID-19,” “SARS-CoV-2,” “coronavirus,” “insulin resistance,” and “diabetes.” Only articles that were directly applicable to insulin resistance in COVID-19 and diabetes was reviewed. RESULTS: Current data shows an increased risk of mortality in patients with diabetes and COVID-19 compared to those without diabetes. COVID-19 triggers insulin resistance in patients, causing chronic metabolic disorders that were non-existent prior to infection. CONCLUSION: Patients with diabetes are more susceptible to COVID-19 infection than those without diabetes. ACE2 expression decreases with infection, exaggerating Ang II activity with subsequent insulin resistance development, an exaggerated immune response and severe SARS-COV-2 infection. Primary Care Diabetes Europe. Published by Elsevier Ltd. 2021-08 2021-04-08 /pmc/articles/PMC8031259/ /pubmed/33849817 http://dx.doi.org/10.1016/j.pcd.2021.04.004 Text en © 2021 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review
Govender, Nalini
Khaliq, Olive P.
Moodley, Jagidesa
Naicker, Thajasvarie
Insulin resistance in COVID-19 and diabetes
title Insulin resistance in COVID-19 and diabetes
title_full Insulin resistance in COVID-19 and diabetes
title_fullStr Insulin resistance in COVID-19 and diabetes
title_full_unstemmed Insulin resistance in COVID-19 and diabetes
title_short Insulin resistance in COVID-19 and diabetes
title_sort insulin resistance in covid-19 and diabetes
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8031259/
https://www.ncbi.nlm.nih.gov/pubmed/33849817
http://dx.doi.org/10.1016/j.pcd.2021.04.004
work_keys_str_mv AT govendernalini insulinresistanceincovid19anddiabetes
AT khaliqolivep insulinresistanceincovid19anddiabetes
AT moodleyjagidesa insulinresistanceincovid19anddiabetes
AT naickerthajasvarie insulinresistanceincovid19anddiabetes